Sign In
Buy AVDL
$21.64
+0 (+0%)
At Close: May 08, 2026
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
08:00am, Thursday, 31'st Aug 2023
DUBLIN, Ireland, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that mem
Avadel Pharmaceuticals: A Resilient Buy; A Comprehensive Assessment Of Potential Prospects
11:20pm, Monday, 21'st Aug 2023
Avadel's Q2 2023 earnings report shows promising growth and FDA endorsement of Lumryz for narcolepsy treatment. Lumryz has seen positive commercialization with high prescriber enrollments and reimburs
Avadel Pharmaceuticals plc (AVDL) Q2 2023 Earnings Call Transcript
02:02pm, Wednesday, 09'th Aug 2023
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Austin Murtagh - Stern Investor Relations Gregory Divis - Chief Executive Offi
Avadel Pharmaceuticals: Winning Is Sweet
03:26pm, Thursday, 20'th Jul 2023
Avadel Pharmaceuticals plc finally won approval of Lumryz™ (sodium oxybate), despite cutthroat opposition from Jazz Pharmaceuticals plc. Potential sales estimate is $3bn. Avadel Pharmaceuticals is f
Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference
08:00am, Thursday, 01'st Jun 2023
DUBLIN, Ireland, June 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that mem
Why Shares of Avadel Soared This Week
03:44pm, Friday, 05'th May 2023
Avadel said it plans to launch its lead therapy to treat excessive daytime sleepiness in adults with narcolepsy, in early June. The company had no revenue in the first quarter.
Avadel: Sleeping Soundly, Why We're Giving A 'Buy' Rating Ahead Of Lumryz Launch
08:20am, Wednesday, 19'th Apr 2023
Avadel: Sleeping Soundly, Why We're Giving A 'Buy' Rating Ahead Of Lumryz Launch
Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference
08:00am, Monday, 10'th Apr 2023
DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that me
Avadel Pharmaceuticals plc (AVDL) Q4 2022 Earnings Call Transcript
09:25pm, Friday, 31'st Mar 2023
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Austin Murtagh – Stern Investor Relations Greg Divis – Chief Executive Off
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30
09:27pm, Wednesday, 29'th Mar 2023
DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it
Avadel Pharmaceuticals: Real-World Data Supports Market Opportunity For Lumryz
01:42pm, Sunday, 12'th Mar 2023
Avadel Pharmaceuticals' Lumryz has the potential to transform the narcolepsy treatment market. Avadel estimates that the total potential patient population for Lumryz could be greater than 30,000, wit
Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
08:00am, Wednesday, 08'th Feb 2023
DUBLIN, Ireland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that mem
Avadel: Lumryz Overhang Now Removed, Rate Buy
05:00am, Wednesday, 07'th Dec 2022
Lumyrz overhang now removed with competitor ordered to delist patent from FDA's Orange Book. The treatment has potential to create a remedial breakthrough in narcolepsy.
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
08:00am, Tuesday, 22'nd Nov 2022
DUBLIN, Ireland, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that mem
Avadel Pharmaceuticals plc (AVDL) Q3 2022 Earnings Call Transcript
01:54pm, Wednesday, 09'th Nov 2022
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q3 2022 Earnings Conference Call November 9, 2022 8:00 AM ET Company Participants Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of
